Investment analysts at William Blair increased their Q2 2025 EPS estimates for shares of Incyte in a research note issued on Tuesday, March 18th. William Blair analyst M. Phipps now expects that the ...

Incyte (NASDAQ:INCY – Get Free Report) was downgraded by William Blair from an “outperform” rating to a “market perform” rating in a note issued to investors on Tuesday, Marketbeat.com reports.

Incyte (NASDAQ:INCY – Free Report) had its price target reduced by Truist Financial from $74.00 to $72.00 in a report issued on Tuesday,Benzinga reports. They currently have a hold rating on the ...

Chung et al. examine the levels of glycoprotein non-metastatic melanoma protein B (GPNMB) in the blood of patients with renal cell carcinoma who acquire resistance to immune checkpoint inhibitor ...

Wojciech Jurczak, MD, PhD, ​​discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase ...

IntroductionProgrammed cell death protein 1 (PD-1) and its ligand, PD-L1, are crucial immune checkpoints that regulate the ...

Monte Rosa has unveiled new data from two trials of its pipeline of molecular glue degraders, notably MRT-6160 and MRT-23.

Guggenheim lowered shares of Incyte (NASDAQ:INCY – Free Report) from a buy rating to a neutral rating in a report issued on Tuesday, Marketbeat Ratings reports. They currently have $92.00 price ...

Feb. 4, 2025 — Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells in ... Feb. 4, 2025 — Researchers have ...

Mar. 19, 2025 — The cells that make up the walls of the finest of all lymphatic vessels have a lobate, oak leaf-like shape that makes them particularly resilient to changes in fluid volume.

The Community Health Council of Rutherford County will offer a free skin screening event from 9 a.m. to noon on Saturday, April 5. The screening will take place in the ...